"Ambarella's stock faces a sharp 21.41% drop due to reduced sales guidance, shaking investor confidence. Other companies, like biotech firms OCS, Co-Diagnostics, and Akari Therapeutics, also experience significant volatility due to factors such as insider transactions and sector shifts. These fluctuations underscore the need for investors to stay updated on industry and company news." Read more

"Cencora director Dermot Mark Durcan makes a notable insider purchase amidst challenging times. The acquisition of 4,000 shares underscored confidence in corporate future, occurring concurrently with a securities fraud probe, new stock buyback plan, and Q2 financial strains. Watch this space for further updates on Cencora's investment prospects." Read more